Asia
Wanbangde Pharmaceutical Gers US FDA Clearance for Myasthenia Gravis Drug Study
Wanbangde Pharmaceutical (SHE:002082) received the approval of the U.S. Food and Drug Administration for a multiple-dose escalation clinical study of WP107 oral solution in healthy participants for the treatment of generalized myasthenia gravis, according to a Friday filing with the Shenzhen bourse.Shares of the pharmaceutical company closed 4% lower Friday.
SHE:002082
